Home » Topics » BioWorld Science

BioWorld Science
RSS

Phase Ib data reported for ITPP in patients with hepatopancreatobiliary tumors

Aug. 16, 2021

Phase I study of tyrosine kinase 2 inhibitor ICP-332 begins in China

Aug. 16, 2021

Lomecel-B improves physical function in phase IIb study in patients with aging frailty

Aug. 16, 2021

Primary endpoint not met in phase II trial of trimodulin in patients with severe COVID-19

Aug. 16, 2021

Apeximmune Therapeutics describes anti-B7-H4 constructs for cancer

Aug. 16, 2021

Beijing Jacobio Pharmaceuticals presents new AURK1 inhibitors

Aug. 16, 2021

Kangpu Biopharmaceuticals divulges CRBN-binding isoindolines

Aug. 16, 2021

MedImmune patents new ADCs for cancer

Aug. 16, 2021

TYK2 inhibitor NDI-034858 enters phase II investigation for plaque psoriasis

Aug. 16, 2021

Trial starts enrollment to assess LY-3361237 in patients with psoriasis

Aug. 16, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 8, 2026.
New York University identifies new analogues of mannose-6-phosphate
BioWorld Science
New York University has discovered new analogues of mannose-6-phosphate reported to be potentially useful for the treatment of memory impairment,...
ASCO 2026: Chinese biopharma arrives at ASCO with pivotal wins
BioWorld
If the 2026 American Society of Clinical Oncology (ASCO) annual meeting in Chicago from May 30 to June 3 demonstrated anything about the evolution of China’s...
Bial-Portela discovers new OX1 receptor antagonists
BioWorld Science
Bial-Portela & Ca SA has patented new orexin OX1 receptor antagonists potentially useful for the treatment of anxiety disorders, depression, eating disorders,...
FB-7033 demonstrates efficacy in MASH management
BioWorld Science
17-β-Hydroxysteroid dehydrogenase 13 (HSD17B13) and lipid transferase CIDEB are known to contribute to metabolic dysfunction-associated steatohepatitis (MASH)...